Related Experiment Videos
Switching and combining of dopamine agonists
Susann Junghanns1, Theresa Glöckler, Heinz Reichmann
1Department of Neurology, Carl Gustav Carus University Dresden, Fetscherstrasse 74, 01307 Dresden, Germany. Susann.Junghanns@neuro.med.tu-dresden.de
Journal of Neurology
|January 29, 2005
Summary
Dopamine agonists are safe and effective for early Parkinson's disease, reducing motor complications compared to levodopa. Switching or combining dopamine agonists can delay the need for levodopa therapy.
Area of Science:
- Neurology
- Pharmacology
Background:
- Dopamine agonists are established as safe and effective initial therapy for early Parkinson's disease.
- Clinical trials show dopamine agonist therapy reduces the risk of motor complications compared to levodopa.
Purpose of the Study:
- To explore reasons for switching dopamine agonists in Parkinson's disease treatment.
- To evaluate the combination of dopamine agonists as a strategy to delay levodopa initiation.
Main Methods:
- Review of prospective long-term clinical trials.
- Analysis of recent data on dopamine agonist switching and combination therapy.
Main Results:
- Initial treatment with dopamine agonists is associated with a lower risk of motor complications than levodopa.
- Switching between dopamine agonists is a common clinical practice.
- Combining two dopamine agonists is a viable strategy to postpone levodopa therapy.
Conclusions:
- Dopamine agonists offer a favorable risk profile for initial Parkinson's disease management.
- Strategies involving switching or combining dopamine agonists provide alternatives to delay levodopa use.